Investigators reported that autonomic symptoms are common from the earliest clinical stages of Parkinson's disease and increase over time. At baseline, 71% of PD participants had more than one affected autonomic domain on the SCOPA-AUT; among the subset with five-year follow-up (n reported in source), 85% met that threshold after five years. The healthy control group also showed some rise: 40% had >1 affected autonomic domain at baseline and 46% of those with five-year follow-up remained above that cutoff. These numbers indicate a high and rising burden of autonomic dysfunction in this biologically confirmed PD cohort across early disease years.
The authors noted that gastrointestinal and urinary symptoms were the most prevalent autonomic complaints among PD participants. Short, direct observation: these two domains dominated the SCOPA-AUT profile. Longer view: the pattern persisted across annual assessments, indicating domain-specific continuity rather than isolated or transient complaints. The source did not report granular item-level frequencies beyond domain predominance, so additional breakdowns (for example, constipation versus gastroparesis rates) were not provided in the preprint.
The cohort showed increasing use of medications addressing constipation and urinary dysfunction over time. Investigators observed rising treatment rates in PD participants, consistent with worsening or persistent symptoms that prompted therapeutic interventions. Cardiovascular comorbidities were also common at baseline in both PD and healthy control groups, and their prevalence increased over the follow-up interval. The preprint did not supply specific medication classes, dosing regimens, or exact comorbidity incidence rates beyond the aggregated trend descriptions.
Data indicated that greater autonomic symptom burden at baseline predicted more rapid cognitive decline during follow-up, with the statistical association reported as p=0.002. The study team emphasized that this relationship was driven primarily by participants with severe autonomic symptoms. In contrast, baseline autonomic burden did not predict accelerated motor deterioration measured by the MDS-UPDRS in this analysis. Concise interpretation: autonomic symptom severity at onset tracked with later cognitive outcomes but not with motor progression in this dataset.
The authors analyzed data from 874 PD participants and 252 healthy controls enrolled in the Parkinson Progression Markers Initiative (PPMI). Autonomic function was measured annually for up to five years using the SCOPA-AUT instrument; affected autonomic domains were defined as a domain subscore greater than 1. Longitudinal changes were evaluated with generalized estimating equations; models adjusted for age, sex, medication use, and comorbidities. The preprint states that longitudinal analyses were restricted to participants with at least one annual follow-up due to adjustment for baseline response. The paper did not provide additional methodological details such as imputation strategy for missing items or model covariance structures in the abstract.
This report is a preprint and has not undergone peer review; investigators noted that their work used de-identified PPMI data and represented a secondary analysis. Longitudinal analyses were limited to participants with at least one follow-up, a selection that the authors explicitly cited as a constraint. The source did not report detailed item-level autonomic data, specific medication classes or doses, or the precise number of participants completing each yearly visit in the abstract; those data may appear in the full manuscript or supplementary files. Open clinical questions documented by the study include whether early autonomic symptom treatment alters the observed cognitive trajectory, which mechanisms link autonomic dysfunction to cognition in PD, and how generalizable these findings are beyond this PPMI biologically confirmed cohort. The final lines of the preprint emphasize the need for further peer-reviewed analyses and for studies that can test whether targeted management of autonomic symptoms modifies downstream cognitive outcomes.